A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

NCT06241599 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: GP/PFLL+AK104
DRUG: GP/PFLL+placebo

Sponsor

Sun Yat-sen University